Skip to content
TrialScanner

NCT05680818

Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1

Phase 3Active, not recruitingBBIOLead

Registry record

Lead sponsor
Calcilytix Therapeutics, Inc., a BridgeBio company
Conditions
Autosomal Dominant Hypocalcemia (ADH)
Primary completion
Aug 22, 2025Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05680818 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05680818: Efficacy and Safety of... | TrialScanner